Lymphomas

Expert faculty review and share their insights on key findings in lymphomas presented at the 2023 ASH Annual Meeting.

Share

Program Content

Activities

  • Lymphoma Updates 2023
    Conference to Clinic: Lymphoma Updates 2023
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 11, 2024

  • ASH 2023: Lymphomas and CLL
    Key Studies in Lymphomas and CLL: Independent Coverage of ASH 2023
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 06, 2024

    Expires: March 05, 2025

Activities

TRANSCEND CLL 004 Update
TRANSCEND CLL 004: 24-Mo Follow-up of Lisocabtagene Maraleucel in Relapsed/Refractory CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

EPCORE NHL 5
EPCORE NHL-5: Results From Arm 1 of a Phase Ib/II Trial Evaluating SC Epcoritamab + Lenalidomide in Relapsed/Refractory DLBCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

ELARA 3-Year Follow-up
Phase II ELARA: 3-Year Follow-up of Tisagenlecleucel in R/R Follicular Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

ELEVATE TN: 6 Yr Update
ELEVATE-TN 6-Yr Update: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

TRANSCEND FL at ASH 2023
TRANSCEND FL: Lisocabtagene Maraleucel as Second-Line Therapy for Patients With High-Risk R/R Follicular Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

ELM-2 Exploratory ctDNA Analysis
ELM-2 Exploratory Analysis: Association Between ctDNA-Assessed Measurable Residual Disease Status and PFS With Odronextamab in R/R FL and DLBCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

1L Mosunetuzumab SC for FL
Mosunetuzumab SC as First-line Therapy for Patients With High Tumor Burden Follicular Lymphoma: Results of a Phase II Study
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

AN + AD in Early cHL
Phase II Study of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine in Early-Stage Classical Hodgkin Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

ELM-2 Final Analysis
ELM-2: Final Analysis From Phase II Trial of Odronextamab in Relapsed/Refractory DLBCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

SWOG S1826
SWOG S1826: Nivolumab-AVD vs BV-AVD in Older Patients (Aged ≥60 Years) With Advanced Stage Classic Hodgkin Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

SYMPATICO
SYMPATICO: Phase III Trial of Ibrutinib + Venetoclax vs Ibrutinib + Placebo for Patients With R/R Mantle Cell Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

BOVen in 1L TP53mut MCL
BOVen: Phase II Trial of Zanubrutinib, Obinutuzmab, and Venetoclax in Treatment-Naive TP53-Mutated Mantle Cell Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

VALENTINE-PTCL01
VALENTINE-PTCL01: Primary Results of Phase II Trial of Valemetostat Tosylate in Patients With Relapsed/Refractory Peripheral T-Cell Lymphomas
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.